ArticleNature communications2018
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 318 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
318 citing papers in PubMed.
- Efficacy and biomarker exploration of anlotinib plus penpulimab in second-line ES-SCLC: Results from the phase 2 ALTER-L041 trial.Cell reports. Medicine · 2026Trial
- Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial.Signal transduction and targeted therapy · 2025Trial
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma.Translational oncology · 2026Article
- Single-cell and machine learning-based neural regulation signature for prognosis prediction and immunotherapy response in lung adenocarcinoma.Translational oncology · 2026Article
- Pulmonary metastasectomy and response-adapted preoperative surveillance in resectable metastatic osteosarcoma: a single-center retrospective cohort study with long-term follow-up.Translational lung cancer research · 2026Article
- PSMB8: an immune-related prognostic marker for low-grade gliomas.Translational cancer research · 2026Article
- IFITM3 promotes an M2-like tumor-supportive microenvironment in acute myeloid leukemia.Medical oncology (Northwood, London, England) · 2026Article
- Large-scale and high-resolution mass spectrometry-based proteomics defines molecular subtypes of nasopharyngeal carcinoma for therapeutic targeting.Signal transduction and targeted therapy · 2026Article
- Integration of bulk and single-cell RNA-seq data identifies a cellular senescence-related prognostic signature in liver hepatocellular carcinoma.Discover oncology · 2026Article
- Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma.Cell reports. Medicine · 2026Article
- Advantages of magnetic compression in rat colonic anastomosis: a comparative study with a transcriptomic perspective.Scientific reports · 2026Article
- Insulin-like growth factor binding protein-3 serves as a biomarker for resistance to enzalutamide in prostate cancer.Apoptosis : an international journal on programmed cell death · 2026Article
- Development of a G2/M checkpoint subtype classifier for guiding precision therapy in liver hepatocellular carcinoma patients.Cancer cell international · 2026Article
- Multi-omics analysis reveals that CAPG positive macrophages are key immunosuppressive drivers and prognostic determinants in the ferroptosis landscape of hepatocellular carcinoma.Discover oncology · 2026Article
- CD168 in lung adenocarcinoma: prognostic relevance, immune feature associations, and MAPK/ERK pathway enrichment.Medical oncology (Northwood, London, England) · 2026Article
- Identify the PANoptosis signature and prognostic model via a multimachine-learning computational framework for bladder urothelial carcinoma.Cancer cell international · 2026Article
- SLC2A1Nature cell biology · 2026Article
- Machine learning identifies glycosphingolipid signature linking immune dysregulation and clinical prognosis in uveal melanoma.Discover oncology · 2026Article
- Development and validation of a diagnostic machine learning model for gastric cancer risk based on double-negative T cell-related features.Cancer cell international · 2026Article
258 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Combining whole exome sequencing, transcriptome profiling, and T cell repertoire analysis, we investigate the spatial features of surgically-removed biopsies from multiple loci in tumor masses of 15 patients with non-small cell lung cancer (NSCLC). This revealed that the immune microenvironment has high spatial heterogeneity such that intratumoral regional variation is as large as inter-personal variation. While the local total mutational burden (TMB) is associated with local T-cell clonal expansion, local anti-tumor cytotoxicity does not directly correlate with neoantigen abundance. Together, these findings caution against that immunological signatures can be predicted solely from TMB or microenvironmental analysis from a single locus biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.